within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AA06_Timolol;

model Timolol_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.944444444444445e-06,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.054,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.021,
    k12 = 1.4166666666666668e-05,
    k21 = 1.4166666666666668e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Timolol_1</td></tr><tr><td>ATC code:</td><td>C07AA06_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>54</td><td>L</td></tr>
    <tr><td>clearance:</td><td>25</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Timolol is a non-selective beta-adrenergic antagonist (beta-blocker) used primarily to treat hypertension, angina pectoris, and in ophthalmic form for increased intraocular pressure in glaucoma. It is approved for clinical use and available in systemic and ophthalmic formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported following intravenous administration in healthy adult subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C07AA06_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Timolol_1;
